# Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer

> **NCT01713218** · EARLY_PHASE1 · UNKNOWN · sponsor: **Jean-Luc Van Laethem** · enrollment: 21 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma Resectable

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** Vismodegib
- **PROCEDURE:** Neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT01713218
- **Lead sponsor:** Jean-Luc Van Laethem
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2014-06
- **Final completion:** 2016-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2012-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713218, "Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01713218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*